RA Capital Management Increases Stake in Solid Biosciences with $23.7M Open Market Purchases
SLDB has more than doubled off its 52-week low of $2.41.
Summary
RA Capital Management, a significant investor, has further increased its stake in Solid Biosciences through substantial open market purchases totaling over $23.7 million, demonstrating continued confidence in the company.
Key Events · Ownership and Investor Activity · SLDB
-
Significant Open Market Purchases
RA Capital Healthcare Fund, L.P. acquired 3,155,031 shares of common stock through open market transactions from March 11 to March 17, 2026.
-
Substantial Investment
The aggregate purchase price for these shares totaled $23,710,116.85, representing a material increase in their beneficial ownership.
-
Increased Stake
The reporting persons now beneficially own 9,313,756 shares, representing 9.9% of the company's common stock.
-
Post-News Accumulation
These purchases occurred after the company's recent positive clinical data announcement and participation in a $240 million private placement, indicating continued investor confidence.
Analysis · SLDB · Life Sciences
This Schedule 13D/A filing reveals that RA Capital Management, L.P. and its affiliated funds have made significant open market purchases of Solid Biosciences common stock between March 11 and March 17, 2026. These purchases, totaling over $23.7 million, represent a substantial investment. This follows RA Capital's participation in the recent $240 million private placement announced on March 6th and comes shortly after the company announced positive interim Phase 1/2 clinical data for SGT-003 on March 11th. The continued accumulation of shares by a major institutional investor, particularly after recent positive news and a capital raise, signals strong conviction in the company's future prospects and could be viewed positively by the market.
How filings like this one have moved
In the 30 days to Sep 22, 2026, 34.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLDB was trading at $7.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $604.6M. The 52-week trading range was $2.41 to $8.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.